Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles

Nanomedicine (Lond). 2006 Oct;1(3):321-9. doi: 10.2217/17435889.1.3.321.


Nanomedicine promises to enhance the ability of clinicians to address some of the serious challenges responsible for cardiovascular mortality, morbidity and numerous societal consequences. Targeted imaging and therapy applications with perfluorocarbon nanoparticles are relevant to a broad spectrum of cardiovascular diseases, ranging from asymptomatic atherosclerotic disease to acute myocardial infarction or stroke. As illustrated in this article, perfluorocarbon nanoparticles offer new tools to recognize and characterize pathology, to identify and segment high-risk patients and to treat chronic and acute disease.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Drug Carriers / chemistry
  • Drug Delivery Systems / methods
  • Fluorocarbons / chemistry*
  • Humans
  • Nanomedicine / methods*
  • Nanoparticles / chemistry*
  • Nanotechnology / methods
  • Pharmaceutical Preparations / administration & dosage
  • Pharmaceutical Preparations / chemistry


  • Drug Carriers
  • Fluorocarbons
  • Pharmaceutical Preparations